Time to biochemical failure could be used as surrogate endpoint in treatment: LA prostate cancer
An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure (IBF), or the time it takes for previously treated cancer to return as indicated by prostate specific antigen ...
Dec 20, 2018
0
0